Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q4 2025 value amounting to -$11.8 million.

  • Enanta Pharmaceuticals' Free Cash Flow rose 5364.44% to -$11.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$18.5 million, marking a year-over-year increase of 8086.29%. This contributed to the annual value of -$32.2 million for FY2025, which is 6673.84% up from last year.
  • According to the latest figures from Q4 2025, Enanta Pharmaceuticals' Free Cash Flow is -$11.8 million, which was up 5364.44% from -$7.9 million recorded in Q3 2025.
  • Enanta Pharmaceuticals' 5-year Free Cash Flow high stood at $17.4 million for Q2 2025, and its period low was -$38.8 million during Q4 2022.
  • Its 5-year average for Free Cash Flow is -$19.8 million, with a median of -$21.0 million in 2021.
  • In the last 5 years, Enanta Pharmaceuticals' Free Cash Flow tumbled by 52812.43% in 2021 and then soared by 18270.26% in 2025.
  • Quarter analysis of 5 years shows Enanta Pharmaceuticals' Free Cash Flow stood at -$13.6 million in 2021, then plummeted by 184.56% to -$38.8 million in 2022, then soared by 33.56% to -$25.8 million in 2023, then rose by 0.89% to -$25.5 million in 2024, then skyrocketed by 53.64% to -$11.8 million in 2025.
  • Its Free Cash Flow stands at -$11.8 million for Q4 2025, versus -$7.9 million for Q3 2025 and $17.4 million for Q2 2025.